Progress in Neuro-Psychopharmacology and Biological Psychiatry
Review articlePsychomotor retardation in depression: Biological underpinnings, measurement, and treatment
Research Highlights
► Psychomotor retardation is a major feature of major depressive disorder (MDD). ► Psychomotor retardation can be measured with scales and physiologic measures. ► Psychomotor retardation may predict response to electroconvulsive therapy. ► Psychomotor retardation may have predictive value for response to antidepressants. ► Existing research suggests that this symptom of MDD has biological correlates.
Introduction
Psychomotor retardation has been characterized as a major feature of depression since antiquity. Hippocrates and Aretaeus of Cappadocia both described psychomotor retardation as a characteristic of depression (Sobin and Sackeim, 1997, Whitwell, 1936, Zilboorg, 1944). Darwin also discussed visible psychomotor symptoms and depressed patients who “no longer wish for action but remain motionless and passive, or may occasionally rock themselves to and fro” (Dantchev and Widlocher, 1998, Greden and Carroll, 1981). In the proceeding decades, authors such as Kraepelin expanded on psychomotor retardation, building upon the knowledge of this noteworthy phenomenon by describing how it was more prominent than depressed mood and involved constrained speech, thought, and behavior (Greden and Carroll, 1981, Sobin and Sackeim, 1997).
Presently, psychomotor retardation is regarded as a key aspect of major depressive disorder (MDD) (American Psychiatric Association, 2000, Greden and Carroll, 1981, Widlocher, 1983). In the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM IV-TR), it is one of the 9 core symptoms identified to diagnose MDD (American Psychiatric Association, 2000). Psychomotor retardation is also a principal symptom of MDD with melancholic features (American Psychiatric Association, 2000, Parker, 2005). Despite its long observed prevalence in MDD, the characterization and clinical significance of psychomotor retardation are poorly understood (Greden and Carroll, 1981, Sobin and Sackeim, 1997). This review will examine the biological correlates, measurement, and treatment implications of psychomotor retardation.
The aim of the paper is to provide a synthesis of the literature on psychomotor retardation in depression with the goal of enhanced awareness for clinicians and researchers. Increased knowledge and understanding of psychomotor retardation in major depressive disorder may lead to further research and better informed diagnosis in regards to psychomotor retardation. To carry out a systematic review, the lead author (JSB) performed independent searches in PubMed (1900–2010) database with the following terms: psychomotor retardation, major depressive disorder, motor, speech, melancholia, antidepressant, electroconvulsive therapy (ECT), and scale. The systematic review included only the articles that mentioned psychomotor retardation and at minimum, one other key search term in the abstract. Reference sections were also reviewed for additional sources. A total of 154 articles (English language literature) were included in this review. These studies were between the dates of 1936–2010, from Australia, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Switzerland, United Kingdom, and United States; the methodologies and study designs varied.
Section snippets
Observable characteristics
Psychomotor retardation is unique in regards to depressive symptomatology as it is assessed through direct behavioral observations of speech, facial expression, eye movements, self-touching, posture, and speed and degree of movements (Jones and Pansa, 1979, Parker and Hadzi-Pavlovic, 1996, Sobin and Sackeim, 1997, Widlocher, 1983). Speech has been extensively studied in the context of depression and psychomotor retardation (Greden et al., 1981, Hardy et al., 1984, Sobin and Sackeim, 1997,
Biological correlates of psychomotor retardation in MDD
Previous work has examined the possible pathophysiology of psychomotor changes in mood disorders. It is appealing to consider other neuropsychiatric disorders with psychomotor changes such as schizophrenia, Parkinson's disease and Huntington's disease as these disorders have high incidences of depressive symptomatology. This would also suggest that the basal ganglia play a critical role in psychomotor retardation in mood disorders. The basal ganglia encompass the caudate nucleus, lentiform
Objective measurements of psychomotor retardation
Neuropsychological measures of psychomotor retardation assess its associated cognitive and motor behaviors to provide an objective approach for its quantification (Szabadi et al., 1976). Circadian rhythms and medication are important confounding factors that should be accounted for when measuring psychomotor retardation (Joffe et al., 1987, Moffoot et al., 1994, Parker and Hadzi-Pavlovic, 1996, Sabbe et al., 1997). For example, psychomotor retardation is typically more pronounced in the morning
Psychomotor retardation scales
Increasingly, psychiatrists in research and clinical practice use depression rating scales that assess the severity of depressive symptoms in patients. However, most depression scales have a minimal number of questions that assess psychomotor retardation. For example, the Montgomery–Asberg Depression Rating Scale (MADRS), a scale commonly used depression severity measure in research studies assess “lassitude” but no other items address psychomotor retardation (Fantino and Moore, 2009). The
Predictive value of psychomotor retardation to clinical outcome with antidepressant pharmacotherapy
Pharmacotherapy for depressed patients is guided by treatment algorithms, clinical judgment, and existing evidence from clinical trials. It is the hope that translational genetics and neuroimaging research will one day provide individualized treatment plans. Currently, there is a dearth of scientific evidence to guide individual antidepressant treatment planning (Taylor et al., 2006). Generally, the first line of treatment involves selective serotonin reuptake inhibitors (SSRIs). Atypical
Predictive value of psychomotor retardation to clinical outcome with electroconvulsive therapy
The use of electroconvulsive therapy (ECT) dates back to the 1930s; however, there is still much to learn regarding which subgroups of patients with MDD respond best to the treatment (Buchan et al., 1992, Hickie et al., 1990, Hickie et al., 1996a, Mendels, 1965a, Mendels, 1965b, Mendels, 1965c, Rasmussen, 2003, Weller and Weller, 2000). ECT is typically reserved for patients who do not benefit from other antidepressant treatments, are acutely suicidal or psychotic, or who present with catatonic
Repetitive transcranial magnetic stimulation (rTMS) treatment effect on psychomotor retardation
Repetitive transcranial magnetic stimulation is a treatment option for depression, with increasing use in clinical practice (Schonfeldt-Lecuona et al., 2010). Treatment with rTMS involves using a changing magnetic field to depolarize neurons and trigger action potentials (Ruohonen and Karhu, 2010). In 2008, the FDA cleared the use of rTMS to treat adults with MDD, who have failed at one trial of an antidepressant medication (Ruohonen and Karhu, 2010).
Although currently there is no literature on
Conclusion
The study of psychomotor retardation has significantly broadened the understanding and recognition of this unique symptom far beyond that of Darwin and Kraepelin. Motor symptoms, such as moving and speaking slowly, can now be analyzed quantitatively and studied in further depth. Emerging neuropsychiatric tools may further the understanding of psychomotor aspects of depression (Bajbouj et al., 2006, Loo et al., 2008, Steele et al., 2000). In addition, psychometric assessment scales exist that
Acknowledgements
This publication was supported by Grant Number R25 MH74675 (PI: Graham Emslie) and K23 MH087739 (PI: Shawn McClintock) from the National Institute of Mental Health (NIMH), and Grant Number UL1 RR024982 (PI: Milton Packer) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).
References (156)
Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age
Front Neuroendocrinol
(1993)- et al.
Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report
Psychiatry Res
(2000) - et al.
Psychomotor retardation and agitation in depression. Relationship to age, sex, and response to treatment
J Affect Disord
(1984) - et al.
HF-rTMS treatment decreases psychomotor retardation in medication-resistant melancholic depression
Prog Neuropsychopharmacol Biol Psychiatry
(2010) - et al.
Evidence for impaired cortical inhibition in patients with unipolar major depression
Biol Psychiatry
(2006) - et al.
Visual cognitive dysfunction in depression: an event-related potential study
Electroencephalogr Clin Neurophysiol
(1998) Psychomotor changes in melancholic and atypical depression: unipolar and bipolar-II subtypes
Psychiatry Res
(2002)- et al.
RRS-4: short version of the retardation rating scale to screen for depression in elderly inpatients
Am J Geriatr Psychiatry
(2008) - et al.
A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report
J Affect Disord
(2008) - et al.
Predictors of response to amine-specific antidepressants
J Affect Disord
(1995)
A quantitative neuromotor predictor of antidepressant non-response in patients with major depression
J Affect Disord
Does psychomotor retardation define a clinically relevant phenotype of unipolar depression?
J Affect Disord
Depression and anxiety in hyperthyroidism
Arch Med Res
Motor cortical excitability and clinical response to rTMS in depression
J Affect Disord
Psychomotor monitoring: a promise being fulfilled?
J Psychiatr Res
Speech pause time and the retardation rating scale for depression (ERD). Towards a reciprocal validation
J Affect Disord
Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?
J Affect Disord
Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo
J Affect Disord
Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder
Psychiatry Res
Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression
Biol Psychiatry
Comparative validity of two measures of psychomotor function in patients with severe depression
J Affect Disord
Neo-striatal rCBF correlates of psychomotor slowing in patients with major depression
Psychiatry Res
Motor activity in depressed patients treated with carbamazepine
Biol Psychiatry
Role of the dopaminergic system in depression
Biol Psychiatry
Electrophysiological and behavioral correlates of psychomotor responsivity in depression
Biol Psychiatry
The quantitative assessment of motor activity in mania and schizophrenia
J Affect Disord
Depressive psychomotor disturbance, cortisol, and dexamethasone
Biol Psychiatry
Time-related cognitive deficiency in four different types of depression
Psychiatry Res
Prediction of clinical response in children taking methylphenidate
J Autism Dev Disord
Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression
J Psychopharmacol
Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions
Psychol Med
Motor reactivity, pain threshold and effects of sleep deprivation in unipolar depressives
Psychiatr Clin (Basel)
Mental and psychomotor speed in depression and mania
Br J Psychiatry
Abnormal subjective time experience in depression
Br J Psychiatry
Psychometric characteristics of ideational retardation in depressives
Br J Clin Psychol
Prefrontal-subcortical and limbic circuit mediation of major depressive disorder
Semin Clin Neuropsychiatry
Treatment response in melancholia
Acta Psychiatr Scand Suppl
Who benefits from electroconvulsive therapy? Combined results of the Leicester and Northwick Park trials
Br J Psychiatry
A measure of striatal function predicts motor stereotypy
Nat Neurosci
Phenomenology of major depression from childhood through adulthood: analysis of three studies
Am J Psychiatry
The diagnosis of depressive syndromes and the prediction of E.C.T. response
Br J Psychiatry
Catatonia: clinical aspects and neurobiological correlates
J Neuropsychiatry Clin Neurosci
Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study
Psychopharmacology (Berl)
Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study
J Affect Disord
Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study
J Affect Disord
The measurement of retardation in depression
J Clin Psychiatry
Anxious-retarded depression: relation with plasma vasopressin and cortisol
Neuropsychopharmacology
A double-blind study of minaprine versus amitriptyline in major depression
Neuropsychobiology
The self-reported Montgomery–Asberg Depression Rating Scale is a useful evaluative tool in major depressive disorder
BMC Psychiatry
Cited by (267)
The clinical presentation of major depressive disorder in youth with co-occurring obsessive-compulsive disorder
2024, Journal of Affective DisordersAbnormal stability of spontaneous neuronal activity as a predictor of diagnosis conversion from major depressive disorder to bipolar disorder
2024, Journal of Psychiatric ResearchLinking inter-subject variability of cerebellar functional connectome to clinical symptoms in major depressive disorder
2024, Journal of Psychiatric ResearchChronic pain predicts a worse response to depression treatment, regardless of thyroid function or psychotropics prescribed
2023, Journal of Affective DisordersOscillatory network markers of subcallosal cingulate deep brain stimulation for depression
2023, Brain Stimulation
- 1
UT Southwestern Medical Center Dallas, Department of Psychiatry, Division of Child and Adolescent Psychiatry, 6300 Harry Hines Blvd. Suite 1200, Dallas, TX 75390-8589, USA.
- 2
UT Southwestern Medical Center, Department of Psychiatry, 5323 Harry Hines Blvd., Dallas, TX 75235-8898, USA.